Reporting in Nature, Gray and colleagues identify and characterize a selective allosteric inhibitor of BCR–ABL, GNF-5, that cooperates with ATP competitive inhibitors to inhibit both wild-type ...

Cite this: Abl Tyrosine Kinase Inhibitors for Overriding Bcr-Abl/T315I: From the Second to Third Generation - Medscape - Sep 01, 2008.

Numerous clinical trials of combination treatments using checkpoint inhibitors are now underway as pharmaceutical companies seek ways to improve the response rates. One way in which ABL Bio is ...

Treatment of chronic myeloid leukemia (CML) has changed drastically with the emergence of the Abl tyrosine kinase inhibitor (TKI), imatinib mesylate. However, primary and secondary resistance have ...

Ascentage Pharma Group International (OTCMKTS:ASPHF – Get Free Report) was the recipient of a significant growth in short ...

TERN-701 showed promising early results, with significant molecular responses and a strong safety profile in heavily ...

TERN-701 is an investigational, oral, potent, small molecule allosteric BCR-ABL inhibitor being developed for patients with CML. CARDINAL is a global, multicenter, open-label, two-part Phase 1 ...

Olverembatinib is a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development Program in China and the first third-generation BCR-ABL inhibitor approved by the ...

Terns Pharmaceuticals (TERN) announced encouraging early data from the ongoing dose escalation part of the Phase 1 CARDINAL study evaluating ...

BTIG initiated coverage of Enliven (ELVN) with a Buy rating and $42 price target Enliven is a precision oncology company developing targeted tyrosine kinase inhibitors directed against clinically ...